Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:15 AM ET 8-K
Financial Results Atossa Therapeutics, Inc. ATOS

Atossa Therapeutics Financial Results

Atossa Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided updates on its (Z)-endoxifen clinical programs. The company highlighted a new contingent value rights (CVR) agreement that entitles shareholders to 25% of net proceeds (up to $50 million) from the potential future sale of its first FDA priority review voucher.

Term
Q3 2026

“In recent weeks, we took meaningful steps to enable shareholders to participate in potential future value from our rare disease programs. Our recently announced contingent value rights agreement entitles holders to share in 25% of the net proceeds, up to $50 million, from the sale of the first priority review voucher awarded to Atossa from its rare disease development programs. At the same time, we continued to advance (Z)-endoxifen toward several near-term milestones, including anticipated FDA clearance of our IND applications in Duchenne Muscular Dystrophy and McCune-Albright Syndrome in early 2027.”

Steven C. Quay, M.D., Ph.D., Atossa's Chairman, President and Chief Executive Officer
8:15 AM ET 10-Q
Financial Results Kulr Technology Group, Inc. KULR

Kulr Technology Group Q3 2026 Results: Turns Profitable, Net Income $4.47M

KULR Technology Group reported a significant revenue increase to $7.4 million for the third quarter of 2026, up from $2.5 million in the prior year period. Despite this growth, the company realized a net loss of $46.5 million for the first nine months of 2026, largely driven by a $15.6 million decrease in the fair value of digital assets and increased research and development expenses.

Key figure
Net income $4.47M
8:11 AM ET 10-Q
Financial Results Tyra Biosciences, Inc. TYRA

Tyra Biosciences Q3 2026 Results: Net Loss of $51.1M, Loss Widens

Tyra Biosciences reported a net loss of $51.1 million for the third quarter of 2026, driven by increased research and development expenses. The company significantly strengthened its balance sheet during the first nine months of 2026, raising over $524 million through an at-the-market offering and a separate issuance of common stock and pre-funded warrants.

Key figure
Net loss $51.1M
8:10 AM ET 10-Q
Financial Results Coya Therapeutics, Inc. COYA

Coya Therapeutics Q3 2026 Results: Net Loss of $10.6M, Loss Widens

Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.

Key figure
Net loss $10.6M
8:09 AM ET 10-Q
Financial Results TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences Q3 2026 Results: Net Loss of $8.85M, Loss Narrows

TriSalus Life Sciences reported a net loss of $16.5 million for the nine months ended September 30, 2026, an improvement from a $29.5 million loss in the prior year period. Revenue grew to $33.2 million, while the company strengthened its balance sheet with cash and cash equivalents increasing to $41.1 million.

Key figure
Net loss $8.85M
8:09 AM ET 10-Q
Financial Results Aviat Networks, Inc. AVNW

Aviat Networks Q1 2026 Results: Net Loss of $2.81M

For the three months ended October 2, 2026, Aviat Networks reported a net loss of $2.8 million on total revenues of $102.0 million, a decrease from the $107.3 million in revenue and $0.2 million in net income reported in the prior year period. The decline was driven by lower product and service sales and increased cost of revenues relative to sales, resulting in a gross profit margin decrease from 33.2% to 29.6%.

Key figure
Net loss $2.81M
8:08 AM ET 8-K
Financial Results Corbus Pharmaceuticals Holdings, Inc. CRBP

Corbus Pharmaceuticals Holdings Financial Results

Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.

“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus

“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
8:07 AM ET 8-K
Financial Results TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences Financial Results

TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million, representing 11.3% year-over-year growth driven by increased TriNav unit sales. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million and highlighted recent FDA clearance for its TriNav Advance system.

“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician’s choice.”

Mary Szela, President and Chief Executive Officer

“Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists.”

Mary Szela, President and Chief Executive Officer
8:05 AM ET 8-K
Financial Results Aviat Networks, Inc. AVNW

Aviat Networks Financial Results

Aviat Networks reported fiscal 2027 first quarter results with total revenues of $102.0 million, a 5% decrease year-over-year. Despite the revenue dip, the company achieved record first-quarter bookings of over $150 million, resulting in a book-to-bill ratio of 1.5. The company reported a GAAP net loss of $2.8 million but maintained a non-GAAP net income of $1.5 million.

Term
Q1 2027
8:05 AM ET 8-K
Financial Results Jerash Holdings (US), Inc. JRSH

Jerash Holdings Financial Results

Jerash Holdings reported fiscal 2027 second quarter revenue of $50.3 million, a 19.8% increase year-over-year, driven by higher shipments to U.S. customers. Net income rose significantly to $2.2 million compared to $479,000 in the prior-year period, aided by automation-related efficiency gains and disciplined cost controls. The company issued Q3 revenue guidance of $49 million to $51 million and noted that production facilities are fully booked through June 2027.

Term
Q2 2027

“We delivered a strong quarter of performance, achieving meaningful growth in both revenue and profitability. Over the past several months, we have navigated logistics challenges across the Middle East, including higher import transportation costs driven by regional shipping disruptions and ongoing uncertainty. Despite these headwinds, we expanded margins through strategic early purchases of raw materials, disciplined cost controls, reduced waste, and enhanced operational efficiencies through automation initiatives.”

Sam Choi, Jerash’s chief executive officer

“Our production facilities are fully booked through June 2027, and order in-flow remains strong. To support continued growth and capitalize on new business opportunities, we are actively seeking ways to expand capacity. Renovations at our most recently acquired facility, along with the construction of a third satellite factory supported by the Jordanian government, are expected to be completed by September 2027. Together, these projects are anticipated to increase our production capacity by approximately 15-20 percent, positioning us to meet growing customer demand and support Jerash’s long-term growth objectives.”

Sam Choi, Jerash’s chief executive officer
8:03 AM ET 8-K
Financial Results Tyra Biosciences, Inc. TYRA

Tyra Biosciences Financial Results

Tyra Biosciences reported third quarter 2026 financial results, highlighting a cash position of $700.5 million following a $400 million financing. The company is advancing its '3x3 strategy' for dabogratinib, including positive initial Phase 2 results in NMIBC and preparations for Phase 3 development.

“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients.”

Todd Harris, PhD, President and Chief Executive Officer

“With a strengthened balance sheet following our $400 million financing, TYRA is entering its next phase of growth from a position of strength. We now have the financial resources to advance our dabogratinib 3x3 strategy through late-stage clinical development.”

Todd Harris, PhD, President and Chief Executive Officer
8:02 AM ET 8-K
Financial Results Co-Diagnostics, Inc. CODX

Co-Diagnostics Financial Results

Co-Diagnostics reported Q3 2026 financial results, highlighting a 12% year-over-year reduction in operating expenses and the submission of a 510(k) premarket notification to the FDA for its Flu A/B & RSV test. The company also expanded its platform capabilities through a collaboration with ReadyGo Diagnostics and the launch of cloud infrastructure in India.

Term
Q3 2026
8:02 AM ET 8-K
Financial Results Coya Therapeutics, Inc. COYA

Coya Therapeutics Financial Results

Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.

Term
Q3 2026

“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”

Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics

“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”

Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics
8:02 AM ET 10-Q
Financial Results PMV Pharmaceuticals, Inc. PMVP

PMV Pharmaceuticals Q3 2026 Results: Net Loss of $34.4M, Loss Widens

PMV Pharmaceuticals reported a significant increase in total liabilities to $54.3 million as of September 30, 2026, primarily driven by a new $43.6 million warrant liability. The company's cash and marketable securities totaled approximately $108.5 million, while the accumulated deficit grew to $517.0 million.

Key figure
Net loss $34.4M
8:01 AM ET 10-Q
Financial Results Atossa Therapeutics, Inc. ATOS

Atossa Therapeutics Q3 2026 Results: Net Loss of $5.64M, Loss Narrows

Atossa Therapeutics reported a net loss of $23.7 million for the nine months ended September 30, 2026, compared to $23.8 million in the prior year period. The company's cash position decreased significantly to $20.6 million, leading management to express substantial doubt about its ability to continue as a going concern without additional capital.

Key figure
Net loss $5.64M
8:00 AM ET 8-K
Financial Results PMV Pharmaceuticals, Inc. PMVP

PMV Pharmaceuticals Financial Results

PMV Pharmaceuticals reported a net loss of $34.4 million for the third quarter of 2026, primarily driven by a non-cash loss related to warrant liabilities. The company ended the period with $108.5 million in cash, bolstered by a $50 million public offering in August, which is expected to fund operations into early 2028. Key clinical progress includes the completion of enrollment for the rezatapopt Phase 2 ovarian cancer cohort with an NDA submission planned for Q1 2027.

Term
Q3 2026

“The updated monotherapy interim data demonstrate the potential for rezatapopt to address a significant unmet medical need. The completed $50 million public offering also positions us well to submit an NDA in the first quarter of 2027 seeking accelerated approval for treatment of platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation.”

David Mack, Ph.D., President and Chief Executive Officer
7:56 AM ET 10-Q
Financial Results Lion Copper Corp. LCU

Lion Copper Q3 2026 Results: Turns Profitable, Net Income $281K

Lion Copper Corp. reported a net loss of $10.2 million for the nine months ended September 30, 2026, though it achieved a small net income of $0.3 million in the third quarter. The company's cash position significantly improved to $21.2 million following funding activities related to the Nuton LLC earn-in agreement, though management continues to express substantial doubt about the company's ability to continue as a going concern.

Key figure
Net income $281K
7:53 AM ET 10-Q
Financial Results Paysign, Inc. PAYS

Paysign Q3 2026 Results: Net Income $6.74M, Up 204.1% YoY

Paysign, Inc. reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $87.1 million compared to $59.3 million in the prior year, driven largely by a doubling of Pharma industry revenue. Net income for the nine-month period rose to $18.9 million, up from $6.2 million in 2025, reflecting improved operating leverage and higher interest income.

Key figure
Net income $6.74M · +204.1% YoY
7:51 AM ET 8-K
Financial Results Alliance Laundry Holdings Inc. ALH

Alliance Laundry Holdings Financial Results

Alliance Laundry Holdings reported Q3 2026 net revenues of $461 million, a 5% increase year-over-year driven by volume and pricing benefits in North America. The company raised its full-year Adjusted EBITDA growth guidance to approximately 10% and reduced net leverage to 2.25x following $45 million in debt repayment.

Term
Q3 2026

“Our third quarter results reflect our deep commitment to customers and the strength, resilience and non-discretionary nature of our business model. We continue to invest in our business by expanding our connected equipment platform, deepening our distributor partnerships, and supporting the businesses, operators and people who count on our products every day.”

Michael Schoeb, CEO of Alliance
7:45 AM ET 8-K
Financial Results Hive Digital Technologies Ltd. HIVE

Hive Digital Technologies Financial Results

HIVE Digital Technologies reported Q2 fiscal 2027 revenue of $84.9 million, driven by a 70% year-over-year increase in AI GPU (HPC) revenue to $8.8 million. Despite stable revenue, the company reported a GAAP net loss of $78.7 million due to significant non-cash charges, including $54.9 million in depreciation and a $31.2 million impairment on mining equipment.

Term
Q2 2027

“Our digital infrastructure platform combines established Bitcoin mining operations with a growing AI computing business. Revenue was broadly stable year over year despite a 27% decline in Bitcoin prices, while HPC revenue increased more than 70%.”

Frank Holmes, Co-Founder and Executive Chairman
7:42 AM ET 8-K
Financial Results Kalaris Therapeutics, Inc. KLRS

Kalaris Therapeutics Financial Results

Kalaris Therapeutics reported third quarter 2026 financial results, ending the period with $82.9 million in cash and marketable securities. The company announced a delay in its Phase 1b/2 study of TH103 for nAMD due to a manufacturing supply interruption, with preliminary data now expected in the second half of 2027. Despite the delay, the company successfully completed a technology transfer to a commercial-scale manufacturer and extended its cash runway into 2028.

Term
Q3 2026

“Kalaris made meaningful progress in the third quarter. We continue to enroll and dose nAMD patients in the ongoing Phase 1b/2 study. In addition to progressing the clinical trial, we have successfully completed the tech transfer to a new commercial-scale manufacturer, with initial test batches achieving the target specifications. Given the paramount importance of ensuring critical quality attributes at the scale required for Phase 3 and commercial supply, this was a significant accomplishment in Q3 and strengthens our confidence in our future clinical supply.”

Andrew Oxtoby, Chief Executive Officer
7:41 AM ET 10-Q
Financial Results Xilio Therapeutics, Inc. XLO

Xilio Therapeutics Q3 2026 Results: Net Loss of $5.95M, Loss Narrows

Xilio Therapeutics reported 7,063,982 shares of common stock outstanding as of November 6, 2026. The company highlights its reliance on strategic collaborations with AbbVie and Gilead, and notes potential gross proceeds of $36.2 million in Q4 2026 from the exercise of Series C warrants.

Key figure
Net loss $5.95M
7:36 AM ET 8-K
Financial Results MasterCraft Boat Holdings, Inc. MCFT

MasterCraft Boat Holdings Financial Results

MasterCraft Boat Holdings reported financial results for the first three months of its transition period, with net sales increasing 123.4% to $154.1 million. The growth was driven by the recent merger with Marine Products, which contributed $59.3 million in incremental sales, alongside a 37.4% increase in legacy business sales. The company is transitioning its fiscal year-end to December 31 following the merger completion.

Term
3 months ended Oct 4, 2026

“We delivered results above our expectations in the first quarter of the Transition Period, with total company net sales growing more than 120% year-over-year. Importantly, our legacy business net sales grew 37% and delivered Adjusted EBITDA growth of nearly 140%, reflecting the deliberate product, commercial, and operational actions we have taken across our business to drive premium mix, clean channels, and reduce costs.”

Brad Nelson, Chief Executive Officer

“The success of the next-generation X-Series is a clear example of the strength of our product and portfolio strategy and our ability to translate a deep understanding of our consumers into products that resonate in the market. Combined with our ongoing cost, productivity, and quality initiatives, those actions are driving stronger earnings and margin performance.”

Brad Nelson, Chief Executive Officer
7:35 AM ET 8-K
Financial Results Xilio Therapeutics, Inc. XLO

Xilio Therapeutics Financial Results

Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.

Term
Q3 2026

“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”

René Russo, Pharm.D., president and chief executive officer of Xilio
7:34 AM ET 10-Q
Financial Results Arbutus Biopharma Corp ABUS

Arbutus Biopharma Q3 2026 Results: Turns Profitable, Net Income $59.1M

Arbutus Biopharma reported a significant net income of $223.7 million for the nine months ended September 30, 2026, primarily driven by a $178.4 million settlement payment from Moderna and $67.3 million in dividend income. This represents a major turnaround from a net loss of $29.7 million in the prior year period, significantly strengthening the company's cash position to $264.2 million.

Key figure
Net income $59.1M
7:33 AM ET 8-K
Financial Results Exagen Inc. XGN

Exagen Financial Results

Exagen Inc. reported third quarter 2026 revenue of $18.4 million, a 7% increase year-over-year, driven by growth in test volume and average selling price. The company reduced its net loss to $6.3 million for the quarter and reiterated its full-year 2026 revenue guidance of $72 million to $75 million.

Term
Q3 2026

“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”

John Aballi, President and Chief Executive Officer of Exagen
7:32 AM ET 10-Q
Financial Results Energy Focus, Inc EFOI

Energy Focus Q3 2026 Results: Turns Profitable, Net Income $531K

Energy Focus, Inc. reported a significant increase in cash to $3.3 million as of September 30, 2026, compared to $1.1 million at year-end 2025, while inventories decreased from $2.9 million to $1.0 million. The company highlighted risks regarding its ability to continue as a going concern and its need for additional financing to maintain operations.

Key figure
Net income $531K
7:32 AM ET 8-K
Financial Results Ambiq Micro, Inc. AMBQ

Ambiq Micro Financial Results

Ambiq Micro reported Q3 2026 net sales of $38.1 million, a 110% year-over-year increase driven by strong demand for edge AI solutions. The company achieved its sixth consecutive quarter of sequential revenue growth and expanded its active customer base by 50%. Management issued Q4 revenue guidance of $43.5 million to $44.5 million, signaling continued acceleration in demand.

Term
Q3 2026

“We delivered our sixth consecutive quarter of sequential net sales growth supported by healthy customer demand and strong supply chain partnerships that enabled us to secure capacity and meet growing customer needs. With demand for edge AI accelerating, we expect to deliver a meaningful step-up in net sales in the fourth quarter and another year of strong growth in 2027.”

Fumihide Esaka, CEO of Ambiq

“We believe we are still in the early stages of a significant, multi-year shift toward greater intelligence at the edge. With our differentiated technology, growing portfolio and expanding customer base, we believe Ambiq is well positioned to capture the significant opportunity ahead.”

Fumihide Esaka, CEO of Ambiq
7:31 AM ET 8-K
Financial Results Arbutus Biopharma Corp ABUS

Arbutus Biopharma Financial Results

Arbutus Biopharma reported Q3 2026 financial results, highlighting a strong cash position of $337.5 million following a $178.4 million settlement payment from Moderna. The company also announced expanded patent infringement litigation against Pfizer and BioNTech in Japan and Canada regarding its LNP technology.

Term
Q3 2026

“This has been a busy and productive quarter for the Arbutus team. I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”

Lindsay Androski, President and CEO
7:31 AM ET 8-K
Financial Results Kustom Entertainment, Inc. KUST

Kustom Entertainment Financial Results

Kustom Entertainment reported its first quarter as a pure-play live entertainment and ticketing company following the divestiture of its legacy video business. Total revenue from continuing operations grew 57% to $2.7 million, and the company achieved net income of $2.3 million, significantly bolstered by a $5.0 million gain from discontinued operations.

Term
Q3 2026

“The third quarter was our first full quarter operating exclusively as a live entertainment and ticketing company, and the results show the strength of the business we have built. A 57% revenue expansion in continuing operations, driven by surging TicketSmarter transaction volume, demonstrates the scalability of our platform.”

Stanton E. Ross, Chief Executive Officer of Kustom Entertainment, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.